AbbVie Inc. (ABBV)
AbbVie cuts 2024 profit forecast on acquisition-related expenses
AbbVie on Wednesday lowered its 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in acquisition-related expenses.
AbbVie Stock: A Perfect Dip for Investors to Buy
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.
AbbVie Stock: A Perfect Dip for Investors to Buy
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
Just 1% of all stocks listed on the major U.S. exchanges are Dividend Aristocrats. These are the 67 companies listed on the S&P 500 that have raised their dividends for 25 consecutive years or more.
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
One of the most important sectors in any country's economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results.
3 Retirement All-Stars for Steady Growth and Income
Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years. Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%.
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
The S&P 500 index is up, but not all of its components participated in the rally. Shares of Pfizer have fallen over the past year, and the stock offers a dividend yield now that's much larger than usual.
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
3 Magnificent Stocks Retirees Can Buy and Hold Forever
AbbVie is a Dividend King poised for growth. Gilead Sciences is a stable, low-risk candidate for investors.
If I Had To Retire With 10 Dividend Aristocrats, It Would Be These
If you want a massive dividend snowball: Get the right combination of dividend yield and growth for maximum compounding effect. Dividend Aristocrats may not always be the best choice due to high valuations and low yields. I refine a list of Dividend Aristocrats from 60+ to 10 based on yield and growth rates if I had to pick just 10.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
